

# Clinical trials of increasing hemoglobin concentration for acute myocardial infarction in patients undergoing PCI

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 blood transfusion

Trial	Treatments	Patients	Trials design and methods
<b>liberal blood transfusion strategy vs conservative</b>			
<b>CRIT Pilot</b> <i>ongoing</i> [NCT00126334] n=NA follow-up:	-	acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB or troponin >upper limit of normal); admission to CCU; hematocrit .30 or less	

## References

CRIT Pilot, :

## 2 erythropoietin

Trial	Treatments	Patients	Trials design and methods
<b>epoetin alfa vs placebo</b>			
<b>HEBE III</b> , 2010 n=263/266 follow-up: 6 weeks	single bolus of 60,000 IU epoetin alfa administered intravenously within three hours after a successful PCI versus control	patients with a first ST-elevation MI and a successful PCI	Parallel groups open the Netherlands
<b>erythropoietin vs placebo</b>			
<b>REVEAL</b> [NCT00378352] n=NA follow-up:	Single parenteral administration of erythropoietin at 15,000 Units, 30,000 Units, or 60,000 Units versus placebo	patients after large myocardial infarction	parallel groups double-blind
<b>recombinant human erythropoietin beta vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
<b>REVIVAL-3</b> [NCT00390832] n=NA follow-up:	recombinant human erythropoietin beta 33.333 IU given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) versus placebo	patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention	double-blind Germany

## References

### HEBE III, 2010:

Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ A single dose of erythropoietin in ST-elevation myocardial infarction. *Eur Heart J* 2010 Nov;31:2593-600 [20802250] [10.1093/eurheartj/ehq304](https://doi.org/10.1093/eurheartj/ehq304)

### REVEAL, :

Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. *JAMA* 2011 May 11;305:1863-72 [21558517] [10.1001/jama.2011.592](https://doi.org/10.1001/jama.2011.592)

### REVIVAL-3, :

Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. *Circ Cardiovasc Interv* 2010;3:408-13 [20736448] [10.1161/CIRCINTERVENTIONS.109.904425](https://doi.org/10.1161/CIRCINTERVENTIONS.109.904425)

Steppech B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord* 2017;17:38 [28109258]

Steppech B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord* 2017;17:38 [28109258]

## 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.